<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162015</url>
  </required_header>
  <id_info>
    <org_study_id>19-272</org_study_id>
    <nct_id>NCT04162015</nct_id>
  </id_info>
  <brief_title>A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma</brief_title>
  <official_title>Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether giving nivolumab in combination with pemetrexed and either&#xD;
      cisplatin or carboplatin before surgery is a safe and effective approach to treating&#xD;
      resectable mesothelioma without delaying surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single institution pilot study of nivolumab with pemetrexed and cisplatin or carboplatin prior to surgery for patients with potentially resectable malignant pleural mesothelioma (MPM).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients going to operating room for surgical resection</measure>
    <time_frame>30 days of the initially planned date</time_frame>
    <description>Patients who experience a greater than 30 day toxicity induced delay of surgery will be counted as a failure for the primary feasibility endpoint.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>nivolumab with pemetrexed and cisplatin or carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive two cycles of neoadjuvant therapy with nivolumab 360 mg, pemetrexed 500 mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC=5. Subsequently, they will undergo pleurectomy/decortication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>nivolumab 360 mg</description>
    <arm_group_label>nivolumab with pemetrexed and cisplatin or carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m^2</description>
    <arm_group_label>nivolumab with pemetrexed and cisplatin or carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin or Carboplatin</intervention_name>
    <description>cisplatin 75 mg/m2 or carboplatin AUC=5</description>
    <arm_group_label>nivolumab with pemetrexed and cisplatin or carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70%&#xD;
&#xD;
          -  Pathologic diagnosis of malignant pleural mesothelioma.&#xD;
&#xD;
          -  Potentially resectable by pleurectomy/decortication, as assessed by thoracic surgeon&#xD;
&#xD;
          -  Negative serum pregnancy test in women of childbearing potential&#xD;
&#xD;
          -  Female patients of childbearing potential must agree to use a highly effective form of&#xD;
             contraception for the duration of the study and for at least 5 months after the last&#xD;
             administration of nivolumab and at least 6 months after last administration of&#xD;
             pemetrexed, whichever is longer&#xD;
&#xD;
          -  Male patients with female partners of childbearing potential must agree to use a&#xD;
             highly effective form of contraception for the duration of the study and for at least&#xD;
             7 months after the last administration of nivolumab and at least 3 months after the&#xD;
             last administration of pemetrexed, whichever is longer&#xD;
&#xD;
          -  Adequate archival or fresh tissue for correlative analysis. Archival tissue will be&#xD;
             deemed acceptable as long as their was no interval therapy prior to cycle 1 day 1 of&#xD;
             protocol therapy. If sufficient archival or fresh tissue is not available, then a&#xD;
             repeat biopsy at baseline prior to starting study treatment will be required as long&#xD;
             as medically safe and feasible&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1000/mcL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dl&#xD;
&#xD;
          -  AST and ALT ≤ 3.0 x upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x upper limit of normal&#xD;
&#xD;
          -  Negative HIV serology blood test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with chemotherapy or immunotherapy for mesothelioma&#xD;
&#xD;
          -  Autoimmune disease requiring systemic immune modulating treatment during the past two&#xD;
             years&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Known active hepatitis B or hepatitis C&#xD;
&#xD;
          -  Current use of systemic prednisone at dose ≥ 10 mg daily (or the equivalent dose with&#xD;
             another corticosteroid)&#xD;
&#xD;
          -  Serious concurrent medical illness or another active cancer requiring treatment&#xD;
&#xD;
          -  Active pneumonitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Offin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Offin, MD</last_name>
    <phone>646-449-1778</phone>
    <email>offinm@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marjorie Zauderer, MD</last_name>
    <phone>646-608-3790</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Offin, MD</last_name>
      <phone>646-449-1778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Offin, MD</last_name>
      <phone>646-449-1778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Offin, MD</last_name>
      <phone>646-449-1778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Offin, MD</last_name>
      <phone>646-449-1778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Offin, MD</last_name>
      <phone>646-449-1778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Offin, MD</last_name>
      <phone>646-449-1778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Offin, MD</last_name>
      <phone>646-449-1778</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Surgery</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>19-272</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

